Immunologic and molecular investigations of the patient's peripheral blood leukocytes
. | - 15 d . | . | + 15 d . | . | + 60 d . | . | + 120 d . | . | + 180 d . | . | Control values . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | P1 . | P2 . | P1 . | P2 . | P1 . | P2 . | P1 . | P2 . | P1 . | P2 . | . | |||||
| ALC, × 109/L | 3.93 | 3.07 | 3.4 | 2.57 | 4.44 | 3.24 | 5.29 | 4.05 | 4.64 | 3.39 | 800-4000 | |||||
| CD3+, % | 95 | 93 | 94 | 93 | 96 | 91 | 96 | 92 | 96 | 90 | 70-80 | |||||
| CD4+, % | 28 | 4 | 25 | 5 | 28 | 6 | 28 | 7 | 22 | 8 | 60-80 | |||||
| CD8+, % | 68 | 88 | 69 | 84 | 70 | 85 | 70 | 85 | 75 | 81 | 20-40 | |||||
| CD4+CD45RA+, % | 0.2 | 0.08 | 2 | 0.05 | 2 | 0.06 | ND | 0.03 | 3 | 0.08 | 30-40 | |||||
| CD4+CD45RO+, % | 27 | 3.92 | 23 | 4.95 | 18 | 5.94 | ND | 6.9 | 20 | 7.9 | 30-40 | |||||
| CD8+CD45RA+, % | 12 | 23 | 16 | 17 | 18 | 14 | ND | 6.8 | 17 | 8.1 | 10-20 | |||||
| CD8+CD45RO+, % | 53 | 67 | 43 | 67 | 41 | 74 | ND | 79 | 43 | 73 | 10-20 | |||||
| CD19+, % | 4 | 3 | 5 | 3 | 3 | 2 | 3 | 3 | 3 | 5 | 10-20 | |||||
| CD16/56+, % | 0.5 | 2 | 0.1 | 1.5 | 0.1 | 2 | 0.2 | 0.9 | 0.1 | 1 | 5-10 | |||||
| IgG, g/L | 16.6 | ND | 9.61 | ND | 12.4 | ND | 11.6 | ND | 13.2 | 13.2 | 6.4-12.4 | |||||
| IgA, g/L | 0.26 | ND | < 0.06 | ND | 0.09 | ND | < 0.06 | ND | 0.07 | 2.37 | 0.8-3.4 | |||||
| IgM, g/L | 0.46 | ND | 0.56 | ND | 0.58 | ND | 0.53 | ND | 0.6 | 0.89 | 0.5-1.5 | |||||
| γc integration study | ||||||||||||||||
| PBL | - | - | +* | - | + | + | + | + | + | - | - | |||||
| CD3+ | - | - | - | ND | ND | ND | + | + | + | - | - | |||||
| CD3- | - | - | - | ND | ND | ND | + | ND | + | ND | - | |||||
. | - 15 d . | . | + 15 d . | . | + 60 d . | . | + 120 d . | . | + 180 d . | . | Control values . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | P1 . | P2 . | P1 . | P2 . | P1 . | P2 . | P1 . | P2 . | P1 . | P2 . | . | |||||
| ALC, × 109/L | 3.93 | 3.07 | 3.4 | 2.57 | 4.44 | 3.24 | 5.29 | 4.05 | 4.64 | 3.39 | 800-4000 | |||||
| CD3+, % | 95 | 93 | 94 | 93 | 96 | 91 | 96 | 92 | 96 | 90 | 70-80 | |||||
| CD4+, % | 28 | 4 | 25 | 5 | 28 | 6 | 28 | 7 | 22 | 8 | 60-80 | |||||
| CD8+, % | 68 | 88 | 69 | 84 | 70 | 85 | 70 | 85 | 75 | 81 | 20-40 | |||||
| CD4+CD45RA+, % | 0.2 | 0.08 | 2 | 0.05 | 2 | 0.06 | ND | 0.03 | 3 | 0.08 | 30-40 | |||||
| CD4+CD45RO+, % | 27 | 3.92 | 23 | 4.95 | 18 | 5.94 | ND | 6.9 | 20 | 7.9 | 30-40 | |||||
| CD8+CD45RA+, % | 12 | 23 | 16 | 17 | 18 | 14 | ND | 6.8 | 17 | 8.1 | 10-20 | |||||
| CD8+CD45RO+, % | 53 | 67 | 43 | 67 | 41 | 74 | ND | 79 | 43 | 73 | 10-20 | |||||
| CD19+, % | 4 | 3 | 5 | 3 | 3 | 2 | 3 | 3 | 3 | 5 | 10-20 | |||||
| CD16/56+, % | 0.5 | 2 | 0.1 | 1.5 | 0.1 | 2 | 0.2 | 0.9 | 0.1 | 1 | 5-10 | |||||
| IgG, g/L | 16.6 | ND | 9.61 | ND | 12.4 | ND | 11.6 | ND | 13.2 | 13.2 | 6.4-12.4 | |||||
| IgA, g/L | 0.26 | ND | < 0.06 | ND | 0.09 | ND | < 0.06 | ND | 0.07 | 2.37 | 0.8-3.4 | |||||
| IgM, g/L | 0.46 | ND | 0.56 | ND | 0.58 | ND | 0.53 | ND | 0.6 | 0.89 | 0.5-1.5 | |||||
| γc integration study | ||||||||||||||||
| PBL | - | - | +* | - | + | + | + | + | + | - | - | |||||
| CD3+ | - | - | - | ND | ND | ND | + | + | + | - | - | |||||
| CD3- | - | - | - | ND | ND | ND | + | ND | + | ND | - | |||||
ND indicates not done; ALC absolute lymphocyte counts; — indicates no control value.
Positive signal studied by quantitative PCR shows < 1% level of gene marking